idarubicin has been researched along with Myelomonocytic Leukemia, Chronic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrascosa, JM; Ferrándiz, C; Guinovart, RM | 1 |
| Clark, SJ; Giles, FJ; Kantarjian, HM; Keating, MJ; Pierce, S; Wong, GC | 1 |
1 trial(s) available for idarubicin and Myelomonocytic Leukemia, Chronic
| Article | Year |
|---|---|
Oral idarubicin in patients with late chronic phase chronic myelogenous leukemia or chronic myelomonocytic leukemia.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Female; Humans; Idarubicin; Leukemia, Myeloid, Chronic-Phase; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Remission Induction; Survival Analysis | 2000 |
1 other study(ies) available for idarubicin and Myelomonocytic Leukemia, Chronic
| Article | Year |
|---|---|
[Leukemia cutis arising at the site of injection of a tetanus vaccine booster].
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Etoposide; Fatal Outcome; Humans; Idarubicin; Immunization, Secondary; Leukemia, Myelomonocytic, Chronic; Leukemic Infiltration; Leukosialin; Male; Middle Aged; Radiotherapy, Adjuvant; Shock, Septic; Skin; Tetanus Toxoid | 2010 |